Literature DB >> 27866289

Echocardiographic findings in asymptomatic systemic lupus erythematosus patients.

Abdel GaffarA Mohammed1, Abdulaziz A Alghamdi2, Mohammad A ALjahlan1, Ibrahim A Al-Homood3.   

Abstract

The aim of this study is to use transthoracic echocardiographic (TTE) imaging methods to identify cardiac dysfunction in asymptomatic systemic lupus erythematosus (SLE) patients and to determine the association between echocardiographic findings and serology. This is a prospective cross-sectional study where 50 patients with confirmed diagnoses of SLE were recruited from rheumatology outpatient clinics. Clinical and serological evaluation to confirm the diagnosis of lupus was done in all patients. Fifty SLE patients, 46 (92%) females and 4 (8%) males, were recruited. Anti-double-stranded DNA (Anti-dsDNA), anticardiolipin, lupus anticoagulant, and anti-β2-glycoproteins were positive in 52.1, 32.6, 13.3, and 15.6%, respectively. Transthoracic echocardiogram revealed mitral regurgitation in 16 patients (32%), pericardial effusion in16 patients (32%), aortic regurgitation in five patients (10%), and tricuspid regurgitation in 10 patients (20%). Eleven patients had left ventricular hypertrophy (22%), and eight patients had ventricular systolic dysfunction (16%). Only four patients had ventricular diastolic dysfunction (8%). A significant association between mitral and tricuspid valve regurgitation and positive anti-dsDNA (p < 0.018, p < 0.006, respectively) was found. Positive anticardiolipin antibodies, lupus anticoagulant, and anti-β 2 glycoprotein antibodies were also associated with mitral valve regurgitation (p values 0.044, 0.006, and 0.023), respectively. Active disease assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was found to be associated with increased risk of mitral valvular leaflet thickening (p value 0.028). Performing regular transthoracic echocardiogram in asymptomatic SLE patients is important for early detection and appropriate treatment of cardiac lesions. Clinically quiescent but serologically active disease and presence of antiphospholipid antibodies were associated with structural heart abnormalities.

Entities:  

Keywords:  Antiphospholipid syndrome (APS); anti-double-stranded DNA (dsDNA); Echocardiogram; Systemic lupus erythematosus (SLE); valve

Mesh:

Substances:

Year:  2016        PMID: 27866289     DOI: 10.1007/s10067-016-3486-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Classification criteria for systemic lupus erythematosus: a review.

Authors:  M Petri; L Magder
Journal:  Lupus       Date:  2004       Impact factor: 2.911

2.  Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus--a preliminary report.

Authors:  Jen-Jhy Lin; Hsiu-Bao Hsu; Shung-Shung Sun; Jhi-Joung Wang; Shung-Tai Ho; Chia-Hung Kao
Journal:  Jpn Heart J       Date:  2003-01

3.  Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study.

Authors:  Felix Perez-Villa; Josep Font; Manel Azqueta; Gerard Espinosa; Carles Pare; Ricard Cervera; Joan C Reverter; Miguel Ingelmo; Gines Sanz
Journal:  Arthritis Rheum       Date:  2005-06-15

4.  Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies.

Authors:  S Zuily; V Regnault; C Selton-Suty; V Eschwège; J-F Bruntz; E Bode-Dotto; E De Maistre; P Dotto; C Perret-Guillaume; T Lecompte; D Wahl
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

Review 5.  How to manage patients with cardiopulmonary disease?

Authors:  Amy H Kao; Susan Manzi
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-04       Impact factor: 4.098

6.  Cardiovascular risk assessment and treatment in systemic lupus erythematosus.

Authors:  Jennifer R Elliott; Susan Manzi
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

7.  Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome.

Authors:  Daphna Paran; Elizabeth Fireman; Ori Elkayam
Journal:  Autoimmun Rev       Date:  2004-01       Impact factor: 9.754

8.  Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies.

Authors:  P Nihoyannopoulos; P M Gomez; J Joshi; S Loizou; M J Walport; C M Oakley
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

Review 9.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis.

Authors:  M C Amigo; R García-Torres
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.686

10.  Thrombosis in systemic lupus erythematosus: a review article.

Authors:  Ibrahim A Al-Homood
Journal:  ISRN Rheumatol       Date:  2012-07-30
View more
  4 in total

1.  Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus.

Authors:  Daniel Ruiz; Jim C Oates; Diane L Kamen
Journal:  Am J Med Sci       Date:  2017-07-20       Impact factor: 2.378

Review 2.  Myocarditis: A Clinical Overview.

Authors:  A L P Caforio; G Malipiero; R Marcolongo; S Iliceto
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 3.955

Review 3.  Cardiac Imaging in Systemic Diseases: What the Clinician should Know.

Authors:  Cesar J Herrera; Pamela Pina; Jorge Martinez; Mario J Garcia
Journal:  Curr Cardiol Rev       Date:  2018

4.  Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus.

Authors:  Deng-Ho Yang; Pui-Ying Leong; Sung-Kien Sia; Yu-Hsun Wang; James Cheng-Chung Wei
Journal:  J Clin Med       Date:  2019-06-05       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.